Trials / Completed
CompletedNCT04772989
A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies
A Phase 1/1b Study to Evaluate the Safety and Tolerability of AB308 in Combination With AB122 in Participants With Advanced Malignancies
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 94 (actual)
- Sponsor
- Arcus Biosciences, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase 1/1b, multicenter, open-label, dose-escalation, and dose-expansion study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and clinical activity of AB308 in combination with zimberelimab (AB122) in participants with advanced malignancies.
Conditions
- Advanced Solid Tumor
- Non Small Cell Lung Cancer (NSCLC)
- Melanoma
- Cervical Cancer
- Multiple Myeloma
- Lymphoma, Non-Hodgkin
- Diffuse Large B Cell Lymphoma (DLBCL)
- Gastric Cancer
- Gastroesophageal Junction Adenocarcinoma
- Esophageal Cancer
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AB308 | Administered intravenously (IV) as specified in the treatment arm |
| DRUG | Zimberelimab | Administered IV as specified in the treatment arm |
Timeline
- Start date
- 2021-03-19
- Primary completion
- 2025-08-25
- Completion
- 2025-08-25
- First posted
- 2021-02-26
- Last updated
- 2025-08-28
Locations
22 sites across 3 countries: United States, Poland, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04772989. Inclusion in this directory is not an endorsement.